Literature DB >> 32504724

Dupilumab reduces absenteeism in patients with moderate to severe atopic dermatitis: Pooled results from the LIBERTY AD SOLO clinical trials.

Marjolein de Bruin-Weller1, Eric L Simpson2, Michael Cork3, Zhen Chen4, Jerome Msihid5, Christine Taniou6, Laurent Eckert5, Abhijit Gadkari4, Gaëlle Bégo-Le Bagousse5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32504724     DOI： 10.1016/j.jaad.2020.05.142

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  2 in total

1.  Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry.

Authors:  Lieneke F M Ariëns; Daphne S Bakker; Lotte S Spekhorst; Jorien Van der Schaft; Judith L Thijs; Inge Haeck; Annebeth E Flinterman; Marijke Kamsteeg; Marie L A Schuttelaar; Marjolein S De Bruin-Weller
Journal:  Acta Derm Venereol       Date:  2021-10-19       Impact factor: 3.875

Review 2.  A Review of Phase 3 Trials of Dupilumab for the Treatment of Atopic Dermatitis in Adults, Adolescents, and Children Aged 6 and Up.

Authors:  Jennifer Cather; Melodie Young; Douglas C DiRuggiero; Susan Tofte; Linda Williams; Tayler Gonzalez
Journal:  Dermatol Ther (Heidelb)       Date:  2022-08-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.